Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT) (ADAPT)

Assessment of Diagnostic Accuracy and Performance of Digital Breast Tomosynthesis Compared to Mammography (ADAPT Trial) ADAPT-BX: Recruitment Plan for Initially Asymptomatic Women Referred for Breast Biopsy

The aim of this recruitment plan (ADAPT-BX) is to collect image and technical data on both digital breast tomosynthesis (DBT) and full-field digital mammography (FFDM), along with other subject data including histology results from biopsy specimen examination and cancer classification data from initially asymptomatic women referred for biopsy after recall from screening and diagnostic work-up. These data will be included in a subsequent and prospectively planned pooled analysis described in a separate protocol (ADAPT-BIE) examining superiority of DBT to FFDM for breast cancer diagnosis and other clinical performance measures.

Study Overview

• Status: Terminated
• Conditions: Breast Cancer; Tumors, Breast
• Intervention / Treatment: Device: DBT and FFDM

Detailed Description

ADAPT program consists of 2 recruitment plans (ADAPT-SCR and ADAPT-BX) followed by an off-line read of the images and data collected (ADAPT-BIE). This study involves the comparison of two devices that can identify abnormalities in routine breast screening and diagnostic mammography. Mammography is usually done with full-field digital mammography (FFDM), which takes flat, two-dimensional X-ray images of the breast. Doctors use the two-dimensional images to look for cancers and other abnormal tissue. The purpose of this study is to learn more about the accuracy of full-field digital mammography devices and a new mammography device called digital breast tomosynthesis (DBT). DBT is similar to full-field digital mammography, but can also move around the breast to get X-ray images from different angles, which provides a three-dimensional view that doctors can use to look for cancers and abnormal tissue. Subjects will be recruited from an initially asymptomatic population that have been referred for clinically indicated breast biopsy based on suspicious breast imaging results. Subjects will undergo a DBT mammogram prior to biopsy. If FFDM was not performed within 30 days, subjects will also undergo FFDM prior to biopsy. Results of biopsy(ies) and histopathology, including lesion characteristics, will be recorded and considered as truth if positive for cancer status. Subjects with negative or benign histological findings will be followed for approximately one year (10-16 months) by FFDM and any additional standard of care practice.

• Study Type: Interventional
• Enrollment (Actual): 196
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Villejuif, France, 94805
    • Gustave Roussy
• United States
  • Florida
    • Boca Raton, Florida, United States, 33486
      • Boca Raton Regional Hospital Christine E. Lynn Women's Health and Wellness Institute
  • New Jersey
    • Voorhees, New Jersey, United States, 08043
      • Cooper Health - Cooper Breast Imaging Centers

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 30 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Female

Description

Inclusion Criteria:

• Women aged 30 years or older (≥30 years old);
• Initially asymptomatic women that underwent routine screening FFDM, breast ultrasound (U/S), breast magnetic resonance imaging (MRI) and/or DBT, followed by diagnostic work-up showing one of more abnormalities and referred for breast biopsy within of 30 days before study entry;
• Are able and willing to comply with study procedures;
• Have signed and dated the informed consent form;
• Documented as non-pregnant based on the investigator's medical judgment and in consideration of local clinical practice standards for evidence of non-pregnancy.

Exclusion Criteria:

• Have been previously included in this study;
• Have undergone diagnostic or surgical intervention(s) or procedure(s) on either breast, including mastectomy and cytopunction, before study-related imaging;
• Have breasts too large to be adequately positioned on 24 x 31 centimeter (cm) FFDM digital receptor without anatomical cut off during a DBT examination (or FFDM, if required);
• Have participated in (within the prior 30 days), another trial of an investigational product expected to interfere with study procedures or outcomes;
• Have breast implant(s);
• Have reconstructed breast(s).

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: DBT and FFDM; Subjects underwent 2D breast imaging with full-field digital mammography (FFDM) followed by 3D breast imaging with digital breast tomosynthesis (DBT). Digital Breast Tomosynthesis: 3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device. Full-Field Digital Mammography: 2D imaging of the breast using Full-Field Digital Mammography (FFDM) device.	Device: DBT and FFDM; Subjects underwent breast imaging using each device: DBT and FFDM.; Other Names: Digital Breast Tomosynthesis (3D breast imaging) and Full-Field Digital Mammography (2D breast imaging); 3D breast imaging and 2D breast imaging

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of Participants With DBT, FFDM and Biopsy Specimens Collected.	For each participant, obtain image data using two methods (DBT and FFDM) and obtain histology results of biopsy specimens from women referred for biopsy.	Approximately 8 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Lesion Type Observed by FFDM Imaging	Lesions were characterized based on findings identified during image evaluations performed by qualified readers.	Approximately 8 weeks
Lesion Type Observed by DBT Imaging	Lesions were characterized based on findings identified during image evaluations performed by qualified researchers.	Approximately 8 weeks
Maximum Lesion Dimension as Observed by FFDM	Maximum Length of Lesions (measured in mm) when images were collected using FFDM.	Approximately 8 weeks
Maximum Lesion Dimension as Observed by DBT	Maximum length of lesions (measured in mm) when images were collected using DBT	Approximately 8 weeks
Biopsy Finding of Lesions Per Subject.	Describes histologic cancer and non-cancer findings of lesion biopsy. Cancer status of lesions was reported per subject, not per lesion.	Approximately 8 weeks

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Safety - Device Related Malfunctions	Number of device-related malfunctions by imaging modality.	less than 16 months

Collaborators and Investigators

• Sponsor: GE Healthcare
• Investigators: Principal Investigator: Corinne Balleyguier, MD, Gustave Roussy, Cancer Campus, Grand Paris; Principal Investigator: Lydia Liao, MD, Cooper Health; Principal Investigator: Kathy Schilling, MD, Boca Raton Regional Hospital

Study record dates

Study Major Dates

• Study Start: March 1, 2015
• Primary Completion (Actual): August 29, 2017
• Study Completion (Actual): August 29, 2017

Study Registration Dates

• First Submitted: December 11, 2014
• First Submitted That Met QC Criteria: December 23, 2014
• First Posted (Estimate): December 24, 2014

Study Record Updates

• Last Update Posted (Actual): February 26, 2019
• Last Update Submitted That Met QC Criteria: February 5, 2019
• Last Verified: February 1, 2019

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Neoplasms; Neoplasms by Site; Breast Diseases; Breast Neoplasms
• Other Study ID Numbers: 124.03-2014-GES-0010_2